CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice

Program Overview

Patient Case 1: De Novo, Metastatic, Non-Aggressive Disease

Patient Case 1: Cont’d

August 2017: Bone Scan

Case Discussion Questions

First-Line PALOMA-2 Trial*: PFS Results

MONALEESA-2: PFS Update

MONARCH 3 Trial Data: PFS

Case Discussion Questions

MONARCH-3: PFS Bone-Only Disease

MONARCH-3: PFS Liver Metastases

Case Conclusion

Case Conclusion: Cont’d

Same Patient Case 1 but Patient Progressed

Case Discussion Questions

Key Clinical Trials: PFS

BOLERO-2 Adverse Events

CDK 4 and 6 Inhibitors: Incidence of Neutropenia

Cumulative Incidence of AEs >15% During the First 5 Years of Palbociclib Treatment (n = 83)

Case Conclusion

Case Conclusion: Cont’d

PALOMA-3: Postprogression Therapies

Patient Case 2: De Novo, Progression on Adjuvant AIs With Liver Metastasis

Patient Case 2: Cont’d

May 2017: CT Scan

Case Discussion Questions

MONARCH-3: PFS Liver Metastases

CDK4/6 Inhibitors: Consistency of Response

MONARCH-2: Incidence of Grade 2/3 Diarrhea

Case Conclusion

Case Conclusion: Cont’d

Patient Case 3: De Novo, Metastatic but Aggressive

Patient Case 3: Cont’d

Case Discussion Questions

Patient Case 3: Continuation

Case Conclusion

Concluding Remarks

Abbreviations

Abbreviations (cont)